{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:35:48Z","timestamp":1767922548883,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010453","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,8,3]],"date-time":"2014-08-03T00:00:00Z","timestamp":1407024000000}}],"reference-count":56,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010453.pub2","type":"journal-article","created":{"date-parts":[[2014,8,3]],"date-time":"2014-08-03T10:33:36Z","timestamp":1407062016000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Aspirin as adjunctive treatment for giant cell arteritis"],"prefix":"10.1002","volume":"2014","author":[{"given":"Susan P","family":"Mollan","sequence":"first","affiliation":[{"name":"Queen Elizabeth Hospital; Ophthalmology Department, University Hospitals Birmingham NHS Trust; Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Sharrack","sequence":"additional","affiliation":[{"name":"Medical School, University of Birmingham; Edgbaston UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike A","family":"Burdon","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital; Ophthalmology Department, University Hospitals Birmingham NHS Trust; Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alastair K","family":"Denniston","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital; Ophthalmology Department, University Hospitals Birmingham NHS Trust; Birmingham UK"},{"name":"University of Birmingham, Birmingham and Midland Eye Centre; Academic Unit of Ophthalmology; Dudley Road Birmingham UK B18 7QU"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,8,3]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD010453.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/rheumatology\/ken480","article-title":"High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition","volume":"48","author":"Berger","year":"2009","journal-title":"Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD010453.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7326\/0003-4819-97-5-672","article-title":"Polymyalgia rheumatica: a 10 year epidemologic and clinical study","volume":"97","author":"Chuang","year":"1982","journal-title":"Annals of Internal Medicine"},{"issue":"5-6","key":"10.1002\/14651858.CD010453.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3109\/01658107.2011.611275","article-title":"Temporal arteritis reversal of blindness using anticoagulation and steroids","volume":"35","author":"Dubey","year":"2011","journal-title":"Neuro-Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD010453.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11926-005-0034-7","article-title":"Clinical trials in giant cell arteritis","volume":"7","author":"Espinoza","year":"2005","journal-title":"Current Rheumatology Reports"},{"issue":"10","key":"10.1002\/14651858.CD010453.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1002\/art.22141","article-title":"Antiplatelet and anticoagulant therapy in patients with giant cell arteritis","volume":"54","author":"Lee","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD010453.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0002-9343(01)00770-7","article-title":"Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients","volume":"111","author":"Liozon","year":"2001","journal-title":"American Journal of Medicine"},{"issue":"3 (Suppl 49)","key":"10.1002\/14651858.CD010453.pub2-BIB0007|cit7","first-page":"S57","article-title":"Impact of antiplatelet therapy in the development of severe ischaemic complications and in the outcome of patients with giant cell arteritis","volume":"26","author":"Narvaez","year":"2008","journal-title":"Clinical Experimental Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD010453.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/art.20171","article-title":"Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis","volume":"50","author":"Nesher","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD010453.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.6061\/clinics\/2013(03)OA06","article-title":"Giant cell arteritis: a multicenter observational study in Brazil","volume":"68","author":"Souza","year":"2013","journal-title":"Clinics"},{"key":"10.1002\/14651858.CD010453.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.1957.02970450023007","article-title":"Treatment of temporal arteritis with adrenal corticosteroids: Results in 55 cases in which the lesion was proved at biopsy","volume":"163","author":"Birkhead","year":"1957","journal-title":"Journal of the American Medical Association"},{"issue":"6-7","key":"10.1002\/14651858.CD010453.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"A544","DOI":"10.1016\/j.autrev.2012.01.003","article-title":"Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment","volume":"11","author":"Borchers","year":"2012","journal-title":"Autoimmune Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010453.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/rheumatology\/ket231","article-title":"Genetic component of giant cell arteritis","volume":"53","author":"Carmona","year":"2014","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD010453.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00041327-200503000-00004","article-title":"Predictors of recurrent ischemic optic neuropathy in giant cell arteritis","volume":"25","author":"Chan","year":"2005","journal-title":"Journal of Neuro-Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010453.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/gerona\/gln030","article-title":"Giant cell arteritis and mortality","volume":"64","author":"Crow","year":"2009","journal-title":"Journals of Gerontology. Series A, Biological Sciences and Medical Sciences"},{"issue":"8","key":"10.1002\/14651858.CD010453.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/rheumatology\/keq039a","article-title":"BSR and BHPR guidelines for the management of giant cell arteritis","volume":"49","author":"Dasgupta","year":"2010","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD010453.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","article-title":"Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a double-blind study","volume":"45","author":"Silva","year":"1986","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010453.pub2-BIB0017|cit17","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD010453.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","article-title":"Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study","volume":"122","author":"Evans","year":"1995","journal-title":"Annals of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010453.pub2-BIB0019|cit19","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"issue":"6","key":"10.1002\/14651858.CD010453.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","article-title":"Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis","volume":"83","author":"Gonzalez-Gay","year":"2004","journal-title":"Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010453.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9394(99)80193-7","article-title":"Occult giant cell arteritis: ocular manifestations","volume":"125","author":"Hayreh","year":"1998","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD010453.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000070631","article-title":"Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies","volume":"217","author":"Hayreh","year":"2003","journal-title":"Ophthalmologica"},{"issue":"4","key":"10.1002\/14651858.CD010453.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/art.20172","article-title":"Low dose aspirin in the treatment of giant cell arteritis","volume":"50","author":"Hellmann","year":"2004","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD010453.pub2-BIB0024|cit24","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD010453.pub2-BIB0025|cit25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005323.pub2","article-title":"Steroid sparing drug treatments for giant cell arteritis","author":"Hill","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010453.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A multicenter, randomized, double blind placebo controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD010453.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010453.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2011.11.021","article-title":"Aspirin and immune system","volume":"12","author":"Hussain","year":"2012","journal-title":"International Immunopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD010453.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00041327-200306000-00003","article-title":"Late ipsilateral recurrence of ischemic optic neuropathy in giant cell arteritis","volume":"23","author":"Kim","year":"2003","journal-title":"Journal of Neuro-Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD010453.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","article-title":"Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States","volume":"41","author":"Lawrence","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD010453.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.autrev.2010.05.002","article-title":"Pathogenesis of giant cell arteritis: More than just an inflammatory condition?","volume":"9","author":"Ly","year":"2010","journal-title":"Autoimmune Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010453.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/art.1780310607","article-title":"Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-85","volume":"31","author":"Machado","year":"1988","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD010453.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1093\/rheumatology\/ker265","article-title":"Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors","volume":"50","author":"Mackie","year":"2011","journal-title":"Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD010453.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/ard.2005.042770","article-title":"Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?","volume":"65","author":"Mahr","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD010453.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1002\/art.22754","article-title":"Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis","volume":"56","author":"Mahr","year":"2007","journal-title":"Arthritis and Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD010453.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD010453.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","article-title":"Risk factors for cranial ischemic complications in giant cell arteritis","volume":"83","author":"Nesher","year":"2004","journal-title":"Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010453.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ophtha.2005.01.031","article-title":"Management of the patient with suspected temporal arteritis: a decision-analytic approach","volume":"112","author":"Niederkohr","year":"2005","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1002\/14651858.CD010453.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1167\/iovs.06-1106","article-title":"A Bayesian analysis of the true sensitivity of a temporal artery biopsy","volume":"48","author":"Niederkohr","year":"2007","journal-title":"Investigative Ophthalmology and Visual Science"},{"issue":"6698","key":"10.1002\/14651858.CD010453.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bmj.299.6698.549","article-title":"Death rates and causes of death in 284 consecutive patients with giant cell arteritis confirmed by biopsy","volume":"299","author":"Nordborg","year":"1989","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD010453.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/38.12.1208","article-title":"The epidemiology of biopsy-positive giant cell arteritis: special reference to cyclic fluctuations","volume":"38","author":"Petursdottir","year":"1999","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD010453.pub2-BIB0042|cit42","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012"},{"key":"10.1002\/14651858.CD010453.pub2-BIB0043|cit43","unstructured":"Robson JC Kiran A Maskell J Hutchings A Arden N Dasgupta B The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010453.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-200301000-00001","article-title":"Bilateral vertebral artery occlusion resulting from giant cell arteritis: report of 3 cases and review of the literature","volume":"82","author":"R\u00fcegg","year":"2003","journal-title":"Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010453.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.21075","article-title":"Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"9634","key":"10.1002\/14651858.CD010453.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(08)61077-6","article-title":"Polymyalgia rheumatica and giant-cell arteritis","volume":"372","author":"Salvarani","year":"2008","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD010453.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","article-title":"Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis","volume":"48","author":"Salvarani","year":"2009","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD010453.pub2-BIB0048|cit48","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"11","key":"10.1002\/14651858.CD010453.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1136\/annrheumdis-2013-203641","article-title":"Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis","volume":"71","author":"Serrano","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010453.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jama.287.1.92","article-title":"Does this patient have temporal arteritis?","volume":"287","author":"Smetana","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010453.pub2-BIB0051|cit51","unstructured":"Unizony SH Dasgupta B Fisheleva E Rowell L Schett G Spiera R Design of the tocilizumab in giant cell arteritis trial International Journal of Rheumatology"},{"issue":"19","key":"10.1002\/14651858.CD010453.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1001\/archinte.162.19.2197","article-title":"Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events","volume":"162","author":"Weisman","year":"2002","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010453.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/art.10071","article-title":"Therapeutic effects of acetylsalicylic acid in giant cell arteritis","volume":"46","author":"Weyand","year":"2002","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD010453.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1568-9972(03)00064-8","article-title":"Immunopathways in giant cell arteritis and polymyalgia rheumatica","volume":"3","author":"Weyand","year":"2004","journal-title":"Autoimmune Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010453.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/BOR.0b013e32833ee946","article-title":"IFN-\u03b3 and IL-17: the two faces of T-cell pathology in giant cell arteritis","volume":"23","author":"Weyand","year":"2011","journal-title":"Current Opinion in Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD010453.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010453","article-title":"Aspirin as adjunctive treatment for giant cell arteritis","author":"Mollan","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010453.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T21:41:42Z","timestamp":1697838102000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010453.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,8,3]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2014,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010453.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,3]]}}}